LignaMed Overview

  • Founded
  • 2013

  • Status
  • Private

  • Employees
  • 3

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $916K

  • Investors
  • 4

LignaMed General Information


Developer of molecule therapy intended to offer breakthrough treatments for severe asthma, organ transplant viability, and fibrosis. The company develops therapeutics from flaxseed derivatives obtained through proprietary synthesis processes and also offers an oral treatment for Th2-low asthma, to salvage donor lung organs that are currently not suitable for a lung transplant, enabling patients to improve donor lung storage conditions and extend the donor lung preservation period, as an oral treatment for Pulmonary Fibrosis control and in some cases reverse the progression of the disease.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • 3675 Market Street
  • Suite 200
  • Philadelphia, PA 19104
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

LignaMed Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Grant 01-Sep-2018 $916K Completed
6. Grant 18-Jul-2017 00000 Completed
5. Grant 01-Jan-2020 00.000 Completed Startup
4. Grant 01-Jan-2019 00.000 Completed Startup
3. Grant 01-Jan-2018 00000 Completed Startup
2. Grant 01-Jan-2017 $403K Completed Startup
1. Accelerator/Incubator 10-Mar-2015 Completed Startup
To view LignaMed’s complete valuation and funding history, request access »

LignaMed Patents

LignaMed Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2018283958-B2 Process for the preparation of (s,s)-secoisolariciresinol diglucoside and (r,r)-secoisolariciresinol diglucoside Inactive 12-Jun-2017 000000000
EP-3638220-A4 Process for the preparation of (s,s Pending 12-Jun-2017 000000000
JP-2020523394-A Method for producing (s,s)-secoisolariciresinol diglucoside and (r,r)-secoisolariciresinol diglucoside Pending 12-Jun-2017 000000000
US-20200181187-A1 Process for the preparation of (s,s)-secoisolariciresinol diglucoside and (r,r)-secoisolariciresinol diglucoside Inactive 12-Jun-2017 000000000
CA-3065386-A1 Process for the preparation of (s,s)-secoisolariciresinol diglucoside and (r,r)-secoisolariciresinol diglucoside Pending 12-Jun-2017 C07H1/00
To view LignaMed’s complete patent history, request access »

LignaMed Executive Team (3)

Name Title Board Seat Contact Info
David Leach Chief Executive Officer
Thais Sielecki Ph.D Chief Scientific Officer
Melpo Christofidou-Solomidou Ph.D Founder & Chairman of Scientific Advisory Board
To view LignaMed’s complete executive team members history, request access »

LignaMed Board Members (5)

Name Representing Role Since
James Harris Self Chairman 000 0000
Melpo Christofidou-Solomidou Ph.D LignaMed Founder & Chairman of Scientific Advisory Board 000 0000
Michael Dishowitz Ph.D Self Board Member 000 0000
Philip Sass Ph.D Self Board Observer & Advisor 000 0000
You’re viewing 4 of 5 board members. Get the full list »

LignaMed Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

LignaMed Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
National Aeronautics and Space Administration Government 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
UPstart (Philadelphia) Accelerator/Incubator 000 0000 000000 0
To view LignaMed’s complete investors history, request access »